Claims for Patent: 7,501,455

Summary for Patent: 7,501,455

Title:	Pharmaceutical compositions containing plasma protein
Abstract:	The invention is related to water-soluble products and pharmaceutical formulations in solid or liquid form mainly for parenteral use. They consist of or comprise a therapeutically active substance (having low aqueous solubility and a substantial binding affinity to plasma proteins) and a plasma protein fraction in controlled aggregation state, whereby the said active substance and the said protein fraction are bound to each other by way of non-covalent bonds. It also covers processes for the preparation of the product and pharmaceutical formulation by dissolving the water-insoluble active substance in a water-miscible, pharmaceutically acceptable solvent, combining said solution with the aqueous solution of a plasma protein fraction in controlled aggregation state whereby a true solution is obtained containing the said active substance and the said protein fraction bound together by way of non-covalent bonds. Optionally a further pharmaceutically acceptable auxiliary additive--such as a protein aggregation controller and/or a stabilizer--may be present. The organic solvent is eliminated by dialyzing, ultrafiltrating, diafiltrating and/or lyophilising. The solid products consisting of the active substance and the protein are also protected. On optional dissolution in water clear, liquid compositions are obtained suitable for direct parenteral or other administration. Method of treatment is also covered. A series of water-insoluble substances is enlisted with appropriate protein fractions to be used.
Inventor(s):	Hegedus; Lajos (Budapest, HU), Krempels; Krisztina (Budapest, HU), Paal; Krisztina (Budapest, HU), Petho; Gabor (Budapest, HU)
Assignee:	Sicor, Inc. (Irvine, CA)
Application Number:	10/802,528
Patent Claims:	1. A pharmaceutical composition comprising: a) a therapeutically-active compound having i) an aqueous solubility of less than about 1.times.10.sup.-4 molar; and ii) a substantial binding affinity to plasma proteins where greater than about 90% of the therapeutically-active compound is protein bound in spontaneous equilibrium at room temperature; and b) a plasma protein in controlled aggregation state; where greater than about 98% of the therapeutically-active compound is non-covalently bound to the plasma protein. 2. The pharmaceutical composition of claim 1 where the composition is in solid form. 3. The pharmaceutical composition of claim 1 where the composition is an aqueous solution. 4. The pharmaceutical composition of claim 1 where the composition is a lyophilized solid. 5. The pharmaceutical composition of claim 1 where the therapeutically-active compound is a cytostatic, an antibiotic, a vitamin, an antiinflammatory, an analgesic, an anticonvulsant, an immunosuppressant, an antiepileptic, an anxiolytic, a hypnotic, an antifungal agent, an anticoagulant, a lipid peroxidase inhibitor, a coronary vasodilator, an antiarrythmic agent, a cardiotonic, a uricosuric, an antithrombotic, a steroid hormone, or a photo-sensitizer. 6. The pharmaceutical composition of claim 1 where the therapeutically-active compound is AMPHOTERICIN B.RTM., an adriamicine analogue, apazone, azathioprin, bromazepam, camptothecin, CARBAMAZEPIN.RTM., clonazepam, cyclosporin A, diazepam, dicumarol, digitoxin, dipyridamole, disopyramide, flunitrazepam, gemfibrozil, ketochlorin, ketoconazole, miconazole, niflumic acid, oxazepam, PACLITAXEL.RTM., phenobarbital, phenytoin, progesterone, PROPOFOL.RTM., ritonavir, sulfinpyrazone, suprofene, tacrolimus, tamoxi fen, taxonoid, testosterone, tirilazad, trioxsalen, valproic acid, or warfarin. 7. The pharmaceutical composition of claim 6, where the therapeutically-active compound is PACLITAXEL.RTM., AMPHOTERICIN B.RTM., camptothecin, CARBAMAZEPIN.RTM., cyclosporin A, or PROPOFOL.RTM.. 8. The pharmaceutical composition of claim 7, where the therapeutically-active compound is PACLITAXEL.RTM.. 9. The pharmaceutical composition of claim 8, where the plasma protein is human serum albumin or human gamma globulin. 10. The pharmaceutical composition of claim 9, where the plasma protein is human serum albumin. 11. The pharmaceutical composition of claim 1 where the plasma protein is a serum albumin, an immunoglobulin, a glycoprotein, an interferon, or an interleukin. 12. The pharmaceutical composition of claim 11 where the plasma protein is a human plasma protein. 13. The pharmaceutical composition of claim 11 where the plasma protein is a recombinant plasma protein. 14. The pharmaceutical composition of claim 1, where the therapeutically-active compound is present in a mole/mole ratio to the plasma protein within the range of 1:0.05 to 1:100. 15. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is an injectable form suitable for parenteral administration. 16. A pharmaceutical composition prepared by a process comprising: a) dissolving a therapeutically-active compound in a water-miscible, pharmaceutically acceptable organic solvent; b) dissolving a plasma protein in an aqueous solution; c) adding the organic solvent in step a) to the aqueous solution in step b); d) removing the organic solvent; to form a pharmaceutical composition where greater than 98% of the therapeutically-active compound is non-covalently bound to the plasma protein. 17. The pharmaceutical composition of claim 16 where the therapeutically-active compound is a cytostatic, an antibiotic, a vitamin, an antiinflammatory, an analgesic, an anticonvulsant, an immunosuppressant, an antiepileptic, an anxiolytic, a hypnotic, an antifungal agent, an anticoagulant, a lipid peroxidase inhibitor, a coronary vasodilator, an antiarrythmic agent, a cardiotonic, a uricosuric, an antithrombotic, a steroid hormone, or a photo-sensitizer. 18. The pharmaceutical composition of claim 16 where the therapeutically-active compound is AMPHOTERICIN B.RTM., an adriamicine analogue, apazone, azathioprin, bromazepam, camptothecin, CARBAMAZEPIN.RTM., clonazepam, cyclosporin A, diazepam, dicumarol, digitoxin, dipyridamole, disopyramide, flunitrazepam, gemfibrozil, ketochlorin, ketoconazole, miconazole, niflumic acid, oxazepam, PACLITAXEL.RTM., phenobarbital, phenytoin, progesterone, PROPOFOL.RTM., ritonavir, sulfinpyrazone, suprofene, tacrolimus, tamoxifen, taxonoid, testosterone, tirilazad, trioxsalen, valproic acid, or warfarin. 19. The pharmaceutical composition of claim 16 where the plasma protein is a serum albumin, an immunoglobulin, a glycoprotein, an interferon, or an interleukin.

Details for Patent 7,501,455

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2040-01-28
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2040-01-28
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2040-01-28
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2040-01-28
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2040-01-28
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2040-01-28
Csl Behring Llc	ALBUMINAR, ALBUMINAR-20, ALBUMINAR-25, ALBUMINAR-5	albumin (human)	Injection	103955	03/17/2000		2040-01-28